Proton Radiotherapy Bests Standard Radiotherapy
By MedImaging International staff writers Posted on 17 Feb 2016 |
Proton beam therapy (PBT) to treat medulloblastoma in pediatric patients appears to be as safe as conventional treatment and offers similar survival rates, according to a new study.
Researchers at Massachusetts General Hospital (MGH; Boston, MA, USA) and Brigham and Women's Hospital (Boston, AM, USA) conducted a non-randomized, open-label, phase 2 trial involving 59 patients (aged 3–21 years) with medulloblastoma to assess late complications, acute side-effects, and survival associated with PBT. All patients underwent craniospinal irradiation of 18–36 Gy radiobiological equivalents (GyRBE), followed by a boost dose. The primary outcome was cumulative incidence of ototoxicity at three years; secondary outcomes were neuroendocrine toxic effects and neurocognitive toxic effects, as assessed by intention-to-treat.
The results showed that three years after treatment, progression-free survival was at 83%, and at five years, progression-free survival was 80%; 12% of patients had serious hearing loss, which rose to 16% at five years. Processing speed and verbal comprehension were also affected, but perceptual reasoning and working memory were not. At five years, 55% had problems with the neuroendocrine system, with growth hormone being the most commonly affected. On the other hand, the researchers found no cardiac, pulmonary, or gastrointestinal toxic effects, which are common in patients treated with photon radiotherapy. The study was published on January 29, 2016, in the Lancet Oncology.
“Proton radiotherapy resulted in acceptable toxicity and had similar survival outcomes to those noted with conventional radiotherapy, suggesting that the use of the treatment may be an alternative to photon-based treatments,” concluded lead author Torunn Yock, MD, and colleagues of the MGH Proton Center. “Although there remain some effects of treatment on hearing, endocrine, and neurocognitive outcomes, particularly in younger patients, other late effects common in photon-treated patients were absent.”
PBT is a precise form of radiotherapy that uses charged particles instead of X-rays to deliver a dose of radiotherapy more precisely and with minimal damage to surrounding tissue. Evidence is growing that protons can be effective in treating a number of cancers, in particular children and young people with brain tumors, for whom PBT appears to produce fewer side effects such as secondary cancers, growth deformity, hearing loss, and learning difficulties.
Related Links:
Massachusetts General Hospital
Brigham and Women's Hospital
Researchers at Massachusetts General Hospital (MGH; Boston, MA, USA) and Brigham and Women's Hospital (Boston, AM, USA) conducted a non-randomized, open-label, phase 2 trial involving 59 patients (aged 3–21 years) with medulloblastoma to assess late complications, acute side-effects, and survival associated with PBT. All patients underwent craniospinal irradiation of 18–36 Gy radiobiological equivalents (GyRBE), followed by a boost dose. The primary outcome was cumulative incidence of ototoxicity at three years; secondary outcomes were neuroendocrine toxic effects and neurocognitive toxic effects, as assessed by intention-to-treat.
The results showed that three years after treatment, progression-free survival was at 83%, and at five years, progression-free survival was 80%; 12% of patients had serious hearing loss, which rose to 16% at five years. Processing speed and verbal comprehension were also affected, but perceptual reasoning and working memory were not. At five years, 55% had problems with the neuroendocrine system, with growth hormone being the most commonly affected. On the other hand, the researchers found no cardiac, pulmonary, or gastrointestinal toxic effects, which are common in patients treated with photon radiotherapy. The study was published on January 29, 2016, in the Lancet Oncology.
“Proton radiotherapy resulted in acceptable toxicity and had similar survival outcomes to those noted with conventional radiotherapy, suggesting that the use of the treatment may be an alternative to photon-based treatments,” concluded lead author Torunn Yock, MD, and colleagues of the MGH Proton Center. “Although there remain some effects of treatment on hearing, endocrine, and neurocognitive outcomes, particularly in younger patients, other late effects common in photon-treated patients were absent.”
PBT is a precise form of radiotherapy that uses charged particles instead of X-rays to deliver a dose of radiotherapy more precisely and with minimal damage to surrounding tissue. Evidence is growing that protons can be effective in treating a number of cancers, in particular children and young people with brain tumors, for whom PBT appears to produce fewer side effects such as secondary cancers, growth deformity, hearing loss, and learning difficulties.
Related Links:
Massachusetts General Hospital
Brigham and Women's Hospital
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment